CDMO’s to watch in 2021

CDMO's to watch in 2021

Now more than ever, the world relies on the pharmaceutical industry to help assist their fight against viruses and diseases like COVID-19. Medical resources provide crucial help to businesses and individuals in their fight to get the world back to normal.

In order to take on this challenge, many pharmaceutical companies rely on CDMOs (Contract Development and Manufacturing Organizations) to speed up production. These companies provide efficiency, quality, and reliability in a time when those values are difficult to find. Here are some of the best CDMOs to watch in 2021 as the world leans more on Big Pharma to carry them through the worldwide pandemic. While the world nervously waits for a vaccine to help it carry on with normal life, these companies are stepping up to the plate and providing for a brighter, healthier future.

  • Samsung Biologics

Samsung Biologics announced its plans to expand further globally at the 2021 J.P. Morgan Healthcare Conference. The company has a vast portfolio of success, winning the CMO Leadership Awards for eight years in a row. Despite the overall global slow-down caused by COVID-19, Samsung Biologics was able to continue its rise to success in 2020.

According to CEO John Rim, the company plans to open CDO R&D centers in China, Boston, and Europe. “In the long term, we will solidify our position as a champion in the CMO, CDO, and biosimilar fields, and explore the new areas of drug business based on accumulated innovative technology and experience,” Rim shared.

Samsung Biologics has placed heavy emphasis on flexibility and innovation as the two tools to success in the COVID-19 era. It recently launched a digitized system known as the Enterprise Quality Unified Information System, which allows clients and partners to access what they need. The system has also greatly improved cGMP record tracking, documentation, and assessment.

  • Thermo Fisher Scientific’s Patheon and Fisher Clinical Services

Better known as Patheon, this CDMO is an award-winning company that has taken a leap forward into cell and gene therapy. The company has ramped up production in response to COVID-19 as well. Vice President of service line management at Thermo Fisher Ned Gordon said, “I can’t recall a time that was busier than it is now.”

Patheon boasts the ability to produce medicines that are delivered to over one million patients per day. Their work in cell and gene therapy provides crucial information and services to pharmaceutical companies currently working on and developing COVID-19 vaccines. Cell and gene therapy and vaccines deliver genetic material to an individual’s cells to help provide resistance to the virus or the vaccine itself.

  • Fujifilm Diosynth Biotechnologies

This global CDMO has already begun processing two different COVID-19 vaccines in Texas. In line with Operation Warp Speed, the company will be producing bulk drug substance of NVX CoV2373, Novavax’ vaccine candidate, as the vaccine hits phase 3 clinical testing.

CEO Dr. Gerry Farrell announced, “We are pleased to bring our technical expertise and world-class facilities to support the mission of Operation Warp Speed in bringing a safe and effective vaccine to the world.” Its plant is currently the largest scale-out cell culture manufacturing facility in the United States.

But the success doesn’t stop here. Fujifilm plans on expanding even more facilities beyond the four it already runs in Europe and the United States. Only recently did the company announce plans to establish another facility in Massachusetts in partnership with the Center for Advanced Biological Innovation and Manufacturing.

  • The Center for Breakthrough Medicines

The pandemic and economic slowdown of 2020 could not stop The Center for Breakthrough Medicines, a member of Discovery Labs. The company made plans to build the world’s largest cell and gene therapy facility in Pennsylvania in early 2020. Since then, it has made significant progress in reaching its goal.

While there were some setbacks, biotech exec Audrey Greenberg said the company quickly overcame them. “The team has remained nimble and quickly found ways to enable scientists and biopharma companies by connecting via virtual means. In some ways, this ‘new normal’ resulted in increased efficiency as well as a wider global reach,” she said.

The company is focused on assisting pharmaceutical companies in reducing time and cost when it comes to developing life-saving medication and vaccines.

  • Catalent

Recently recognized as a top United States employer, Catalent has won many battles over the past year in the face of the COVID-19 pandemic. The company stresses that its main mission is to provide patients with the medicine and vaccines they will need to heal from disease and sickness. The expansion in 2020 made major headlines as the company successfully partnered with pharmaceutical companies like Moderna, Johnson & Johnson and AstraZeneca.

Leave a Reply

Your email address will not be published. Required fields are marked *